Impaired_JJ
cortisol_NN
binding_NN
to_TO
glucocorticoid_NN
receptors_NNS
in_IN
hypertensive_JJ
patients_NNS
._.

We_PRP
compared_VBD
glucocorticoid_NN
receptor_NN
binding_NN
characteristics_NNS
and_CC
glucocorticoid_NN
responsiveness_NN
of_IN
human_JJ
mononuclear_JJ
leukocytes_NNS
-LRB-_-LRB-
HML_NN
-RRB-_-RRB-
from_IN
hypertensive_JJ
patients_NNS
and_CC
matched_VBD
normotensive_JJ
volunteers_NNS
._.

We_PRP
also_RB
considered_VBD
associations_NNS
of_IN
these_DT
variables_NNS
with_IN
plasma_NN
renin_NN
activity_NN
,_,
aldosterone_NN
,_,
cortisol_NN
,_,
corticotropin_NN
,_,
and_CC
electrolyte_NN
concentrations_NNS
._.

We_PRP
calculated_VBD
binding_NN
affinity_NN
-LRB-_-LRB-
Kd_NN
;_:
nmol\/L_NN
-RRB-_-RRB-
and_CC
capacity_NN
-LRB-_-LRB-
Bmax_NN
;_:
sites\/cell_NNS
-RRB-_-RRB-
for_IN
dexamethasone_NN
and_CC
cortisol_NN
from_IN
homologous_JJ
and_CC
heterologous_JJ
competition_NN
curves_NNS
for_IN
specific_JJ
-LCB-_-LRB-
3H-RCB-dexamethasone_JJ
binding_NN
sites_NNS
on_IN
HML_NN
isolated_VBN
from_IN
the_DT
blood_NN
of_IN
normotensive_JJ
volunteers_NNS
and_CC
subjects_NNS
with_IN
essential_JJ
hypertension_NN
._.

Glucocorticoid_NN
responsiveness_NN
of_IN
HML_NN
was_VBD
evaluated_VBN
as_IN
IC50_NN
values_NNS
-LRB-_-LRB-
nmol\/L_NN
-RRB-_-RRB-
for_IN
dexamethasone_NN
and_CC
cortisol_NN
for_IN
the_DT
inhibition_NN
of_IN
lysozyme_NN
release_NN
._.

We_PRP
measured_VBD
plasma_NN
hormones_NNS
by_IN
radioimmunoassay_NN
._.

Kd_NN
values_NNS
-LRB-_-LRB-
mean_CD
+_CC
\/_NN
-_:
SE_NN
-RRB-_-RRB-
for_IN
cortisol_NN
in_IN
HML_NN
of_IN
hypertensive_JJ
patients_NNS
were_VBD
higher_JJR
than_IN
in_IN
control_JJ
subjects_NNS
-LRB-_-LRB-
24.6_CD
+_CC
\/_CD
-2.4_CD
versus_CC
17.5_CD
+_CC
\/_RB
-1.7_CD
nmol\/L_NN
,_,
P_NN
&lt;_JJR
.04_CD
-RRB-_-RRB-
._.

Binding_VBG
capacity_NN
-LRB-_-LRB-
4978_CD
+_JJ
\/_:
-391_CD
versus_CC
4131_CD
+_CC
\/_NN
-321_CD
sites\/cell_NNS
-RRB-_-RRB-
,_,
Kd_NN
values_NNS
for_IN
dexamethasone_NN
-LRB-_-LRB-
6.7_CD
+_JJ
\/_:
-0.5_CD
versus_CC
5.7_CD
+_CC
\/_NN
-0.3_CD
nmol\/L_NN
-RRB-_-RRB-
,_,
and_CC
IC50_NN
values_NNS
for_IN
dexamethasone_NN
-LRB-_-LRB-
3.4_CD
+_CC
\/_CD
-0.3_CD
versus_CC
3.1_CD
+_CC
\/_RB
-0.2_CD
nmol\/L_NN
-RRB-_-RRB-
and_CC
cortisol_NN
-LRB-_-LRB-
12.2_CD
+_JJ
\/_:
-1.6_CD
versus_CC
9.5_CD
+_CC
\/_NN
-0.3_CD
nmol\/L_NN
-RRB-_-RRB-
were_VBD
not_RB
significantly_RB
different_JJ
._.

Patients_NNS
with_IN
renin_NN
values_NNS
less_JJR
than_IN
0.13_CD
ng_NN
angiotensin_NN
I\/L_NN
per_IN
second_JJ
were_VBD
markedly_RB
less_RBR
sensitive_JJ
to_TO
cortisol_NN
than_IN
those_DT
with_IN
higher_JJR
values_NNS
._.

Both_CC
Kd_NN
-LRB-_-LRB-
30.3_CD
+_CC
\/_JJ
-2.5_CD
versus_CC
19.2_CD
+_CC
\/_NN
-2.4_CD
nmol\/L_NN
-RRB-_-RRB-
and_CC
IC50_NN
values_NNS
-LRB-_-LRB-
15.5_CD
+_JJ
\/_:
-1.8_CD
versus_CC
8.9_CD
+_CC
\/_NN
-1.2_CD
nmol\/L_NN
-RRB-_-RRB-
for_IN
cortisol_NN
were_VBD
significantly_RB
higher_JJR
in_IN
patients_NNS
with_IN
lower_JJR
renin_NN
values_NNS
-LRB-_-LRB-
P_NN
&lt;_JJR
.03_CD
-RRB-_-RRB-
._.

Other_JJ
variables_NNS
,_,
including_VBG
plasma_NN
hormone_NN
and_CC
electrolyte_NN
values_NNS
and_CC
binding_VBG
characteristics_NNS
for_IN
dexamethasone_NN
,_,
were_VBD
not_RB
different_JJ
._.

These_DT
data_NNS
suggest_VBP
that_IN
cortisol_NN
binding_NN
to_TO
glucocorticoid_NN
receptor_NN
is_VBZ
slightly_RB
impaired_JJ
in_IN
patients_NNS
with_IN
essential_JJ
hypertension_NN
._.

In_FW
vivo_FW
,_,
this_DT
could_MD
lead_VB
to_TO
inappropriate_JJ
binding_NN
of_IN
cortisol_NN
to_TO
mineralocorticoid_NN
receptors_NNS
._.

Hence_RB
,_,
decreased_VBN
sensitivity_NN
to_TO
cortisol_NN
is_VBZ
associated_VBN
with_IN
renin_NN
suppression_NN
._.

This_DT
hypothesis_NN
is_VBZ
supported_VBN
by_IN
evidence_NN
of_IN
hypertension_NN
and_CC
low_JJ
renin_NN
activity_NN
,_,
which_WDT
others_NNS
have_VBP
described_VBN
in_IN
patients_NNS
with_IN
primary_JJ
glucocorticoid_NN
resistance_NN
due_JJ
to_TO
mutations_NNS
of_IN
the_DT
glucocorticoid_NN
receptor_NN
._.

